Naranjo, C. Psychotherapeutic Possibilities of New Fantasy-Enhancing Drugs. Clin. Toxicol., 1 Jan 1969, 2 (2), 209–224. 855 kB. https://doi.org/10.3109/15563656908990930
Naranjo, C. Ibogaine: Fantasy and reality. In The Healing Journey: New approaches to consciousness; , Pantheon Books, New York, 1 Jan 1973; pp 174–228.
Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. https://doi.org/10.1371/journal.pone.0009019
Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1 Jan 1970; pp 21–41. 8.6 MB. #Ibogaine
Meyer, MR; Caspar, A; Brandt, SD; Maurer, HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 β-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal. Bioanal. Chem., 1 Jan 2014, 406 (1), 225–237. 457 kB. https://doi.org/10.1007/s00216-013-7425-9 #Ibogaine LC,MS
Shulgin, AT. Chemistry of psychotomimetics. In Handbook of Experimental Pharmacology. Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs; Hoffmeister, F; Stille, G, Eds., Springer-Verlag, Berlin, 1 Jan 1982; Vol. 55 (3), pp 3–29. 928 kB. https://doi.org/10.1007/978-3-642-67770-0_1 #18
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Shulgin, AT. Hallucinogens. In Burger’s Medicinal Chemistry, 4th ed., Part III; Wolff, ME, Ed., John Wiley & Sons, Inc., 1 Jan 1981; pp 1109–1137. 4.7 MB. #45
Shulgin, AT. Psychotomimetic agents. In Psychopharmacological Agents; Gordon, M, Ed., Academic Press, New York, 1 Jan 1976; Vol. 4, pp 59–146. 3.1 MB. #XVI
Hoffer, A; Osmond, H. The Hallucinogens, Academic Press, New York, . 3.9 MB. #Ibogaine
Barsuglia, JP; Polanco, M; Palmer, R; Malcolm, BJ; Kelmendi, B; Calvey, T. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. In Progress in Brain Research; , Elsevier, 25 Oct 2018; . 1.4 MB. https://doi.org/10.1016/bs.pbr.2018.08.002 #Ibogaine
Wasko, M; Witt-Enderby, PA; Surratt, CK. DARK classics in chemical neuroscience: Ibogaine. ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2475–2483. 5.1 MB. https://doi.org/10.1021/acschemneuro.8b00294 #Ibogaine
Zamberlan, F; Sanz, C; Vivot, RM; Pallavicini, C; Erowid, F; Erowid, E; Tagliazucchi, E. The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Front. Integr. Neurosci., 8 Nov 2018, 12 (54). 5.0 MB. https://doi.org/10.3389/fnint.2018.00054 #Ibogaine
Cameron, LP; Olson, DE. DARK classics in chemical neuroscience: N,N-Dimethyltryptamine (DMT). ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2344–2357. 1.4 MB. https://doi.org/10.1021/acschemneuro.8b00101 #13
Arias, HR; Feuerbach, D; Targowska-Duda, KM; Jozwiak, K. Structure–activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states. Int. J. Biochem. Cell Biol., 1 Sep 2011, 43 (9), 1330–1339. 1.1 MB. https://doi.org/10.1016/j.biocel.2011.05.011 #Ibogaine
Iyer, RN; Favela, D; Zhang, G; Olson, DE. The iboga enigma: The chemistry and neuropharmacology of iboga alkaloids and related analogs. Nat. Prod. Rep., 14 Aug 2020, 38 (2), 307-329. 3.3 MB. https://doi.org/10.1039/D0NP00033G #1
Cameron, LP; Tombari, RJ; Lu, J; Pell, AJ; Hurley, ZQ; Ehinger, Y; Olson, DE. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 1 Jan 2021, 589 (7842), 474–479. 10.5 MB. https://doi.org/10.1038/s41586-020-3008-z #Ibogaine MS,NMR,IR
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #17
Mesley, RJ; Evans, WH. Infrared identification of some hallucinogenic derivatives of tryptamine and amphetamine. J. Pharm. Pharmacol., 1 May 1970, 22 (5), 321–332. 775 kB. https://doi.org/10.1111/j.2042-7158.1970.tb08533.x #Ibogaine IR
Brimblecombe, RW; Pinder, RM. Hallucinogenic agents, Wright-Scientechnica, Bristol, UK, 1 Jan 1975. 46.2 MB. #4.39
Yu, A. Indolealkylamines: Biotransformations and potential drug-drug interactions. AAPS J., 1 Jun 2008, 10 (2), 242–253. 314 kB. https://doi.org/10.1208/s12248-008-9028-5 #Ibogaine